Success Metrics

Active Trials
6(86%)

Phase Distribution

Ph phase_2
1
14%
Ph phase_1
5
71%
Ph phase_3
1
14%

Phase Distribution

5

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
5(71.4%)
Phase 2Efficacy & side effects
1(14.3%)
Phase 3Large-scale testing
1(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

6

trials recruiting

Total Trials

7

all time

Status Distribution
Active(7)

Detailed Status

Recruiting4
Active, not recruiting2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
6
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 15 (71.4%)
Phase 21 (14.3%)
Phase 31 (14.3%)

Trials by Status

not_yet_recruiting114%
recruiting457%
active_not_recruiting229%

Recent Activity

6 active trials
Showing 5 of 7
recruitingphase_2

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

NCT07095452
recruitingphase_1

Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06896916
recruitingphase_3

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06158841
not_yet_recruitingphase_1

ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia

NCT07420959
recruitingphase_1

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib

NCT06892522
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT07095452Phase 2

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Recruiting
NCT06896916Phase 1

Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma

Recruiting
NCT06158841Phase 3

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

Recruiting
NCT07420959Phase 1

ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia

Not Yet Recruiting
NCT06892522Phase 1

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib

Recruiting
NCT05259839Phase 1

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

Active Not Recruiting
NCT05286229Phase 1

A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan

Active Not Recruiting

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7